Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPRI-CF113 is a small molecule drug candidate containing the synthetic progestin drospirenone, currently under development by ASKA Pharmaceutical for the treatment of dysmenorrhea. Drospirenone is unique among synthetic progestins because its pharmacological profile closely resembles natural progesterone, exhibiting potent progestogenic activity alongside antimineralocorticoid and antiandrogenic properties. In the treatment of dysmenorrhea, LPRI-CF113 works by suppressing ovulation and inhibiting the proliferation of the endometrium, which leads to a reduction in the synthesis of prostaglandins—the primary mediators of painful uterine contractions. As of early 2026, the compound is in Phase 1/2 clinical trials in Japan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LPRI-CF113.